skip to navigation skip to content

Financial Times: Novo Nordisk buys UK university biotech spin-out Ziylo


Ziylo’s biotech platform for treating diabetes was acquired for $800 million by Novo Nordisk. Dr Andy Chapman, Chief Scientific Officer of Ziylo, is an alumnus of the Ignite programme, run by the Entrepreneurship Centre at Cambridge Judge Business School.

Read the full article [Add URL domain here []